1.
Minerva Anestesiol
; 88(9): 735-747, 2022 09.
Artículo
en Inglés
| MEDLINE
| ID: mdl-35315621
RESUMEN
Solid organ transplantation is the best therapeutic option for patients with end-stage organ disease and, according to the data from international registries, there has been a steady increase in numbers and results. However, posttransplant infections remain a fearsome complication with, in the last decade, an increasing incidence of episodes due to antibioticresistant bacteria and opportunistic agents. In this paper, we summarized the most relevant and updated knowledge concerning infections from multidrugresistant germs in solid organ transplant recipients, focusing on risk factors, treatment and prevention strategies, and antimicrobial pharmacokinetics relevant to this population of patients.